Clinical

Dataset Information

0

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer


ABSTRACT: This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC).

DISEASE(S): Adenocarcinoma,Gastrointestinal Neoplasms,Biliary Tract Neoplasms,Colorectal Cancer,Colorectal Neoplasms,Her2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, And Colorectal Cancer

PROVIDER: 2303997 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2019-10-12 | GSE138772 | GEO
| EGAS00001000950 | EGA
2022-08-26 | GSE201425 | GEO
2010-06-24 | E-GEOD-22524 | biostudies-arrayexpress
2018-02-14 | GSE90698 | GEO
2015-03-01 | E-GEOD-59856 | biostudies-arrayexpress
2023-05-04 | GSE231369 | GEO
2024-03-27 | GSE233893 | GEO
2020-07-08 | PXD020151 | Pride
2022-08-01 | GSE210065 | GEO